European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease—the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow

INTRODUCTION: In conjunction with the NILVAD trial, a European Multicentre Double-Blind Placebo Controlled trial of Nilvadipine in Mild-to-Moderate Alzheimer's disease (AD), there are four NILVAD substudies in which eligible NILVAD patients are also invited to participate. The main NILVAD proto...

Descripción completa

Detalles Bibliográficos
Autores principales: Meulenbroek, Olga, O'Dwyer, Sarah, de Jong, Daan, van Spijker, Gerrita, Kennelly, Sean, Cregg, Fiona, Olde Rikkert, Marcel, Abdullah, Laila, Wallin, Anders, Walsh, Cathal, Coen, Robert, Kenny, Rose Anne, Daly, Leslie, Segurado, Ricardo, Borjesson-Hanson, Anne, Crawford, Fiona, Mullan, Michael, Lucca, Ugo, Banzi, Rita, Pasquier, Florence, Breuilh, Laetitia, Riepe, Matthias, Kalman, Janos, Molloy, William, Tsolaki, Magda, Howard, Robert, Adams, Jessica, Gaynor, Siobhan, Lawlor, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Geriatric Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964180/
https://www.ncbi.nlm.nih.gov/pubmed/27436668
http://dx.doi.org/10.1136/bmjopen-2016-011584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964180/
https://www.ncbi.nlm.nih.gov/pubmed/27436668
http://dx.doi.org/10.1136/bmjopen-2016-011584

Ejemplares similares